Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner

Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are under active investigation. Here, we re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Feng‐Shu, Chen, Yao‐Li, Hung, Man‐Hsin, Chu, Pei‐Yi, Tsai, Ming‐Hsien, Chen, Li‐Ju, Hsiao, Yung‐Jen, Shih, Chih‐Ting, Chang, Mao‐Ju, Chao, Tzu‐I, Shiau, Chung‐Wai, Chen, Kuen‐Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537702/
https://www.ncbi.nlm.nih.gov/pubmed/28453226
http://dx.doi.org/10.1002/1878-0261.12072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537702/
https://www.ncbi.nlm.nih.gov/pubmed/28453226
http://dx.doi.org/10.1002/1878-0261.12072

Ejemplares similares